Erratum: The effect of azoximer bromide (polyoxidonium®) in patients hospitalized with coronavirus disease (covid-19): An open-label, multicentre, interventional clinical study ((2021) 10 (2021-11-1) DOI: 10.7573/dic.2020-11-1)

The authors wish to make the following corrections to their article: Efimov SV, Matsiyeuskaya NV, Boytsova OV, et al. Corrigendum: The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): An open-label, multicentre, interventional clinical study. Drugs in Context 2021;10: 2021-11-1. DOI: 10.7573/dic.2020-11-1.